NRx Pharmaceuticals Announces Signing of a Development Agreement for the Manufacture of Ketamine to Treat Suicidality and Depression

I think that NRx Pharmaceuticals’ decision to sign a development agreement for the manufacture of ketamine is a great move on their part. It is a promising drug that has been shown to be effective in treating depression and other mental health issues, and it is a great opportunity for NRx to expand their business. I’m sure that this agreement will be beneficial for both parties and I’m looking forward to seeing the results.